Search

Author/Creator Deschatelets, Pascal

1. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Issue 9 (September 2022)

Authors:
de Latour, Régis Peffault; Szer, Jeff; Weitz, Ilene C; Röth, Alexander; Höchsmann, Britta; Panse, Jens; Usuki, Kensuke; Griffin, Morag; Kiladjian, Jean-Jacques; de Castro, Carlos M; Nishimori, Hisakazu; Ajayi, Temitayo; Al-Adhami, Mohammed; Deschatelets, Pascal; Francois, Cedric; Grossi, Federico...
Journal:
Lancet
Issue:
Volume 9:Issue 9(2022)
Page Start:
e648
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Issue 11 (11th September 2020)

Authors:
de Castro, Carlos; Grossi, Federico; Weitz, Ilene Ceil; Maciejewski, Jaroslaw; Sharma, Vivek; Roman, Eloy; Brodsky, Robert A.; Tan, Lisa; Di Casoli, Carl; El Mehdi, Delphine; Deschatelets, Pascal; Francois, Cedric
Journal:
American journal of hematology
Issue:
Volume 95:Issue 11(2020:Nov.)
Page Start:
1334
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. (September 2017)

Authors:
Mehdi, Delphine El; Grossi, Federico V.; Deschatelets, Pascal; Pullon, Humphrey; Tan, Lisa; Vega, Carolina A.; Francois, Cedric G.
Journal:
Molecular immunology
Issue:
Volume 89(2017:Sep.)
Page Start:
115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗